Prominent examples of theranostics include targeting prostate-specific membrane antigen (PSMA) in castration-resistant prostate cancer, where the therapeutic radiopharmaceutical is [177Lu]Lu-PSMA-617 (United States Food and Drug Administration (FDA) approved as Pluvicto® in 2022), and somatostatin receptors (SSTRs) in neuroendocrine tumors (NETs), with [177Lu]Lu-DOTA-TATE (FDA approved as Lutathera® in 2018) as the therapeutic partner 6-8. Here, FOLH1 is linked to prostate cancer.